DTC — Defence Therapeutics Income Statement
0.000.00%
Last trade - 00:00- CA$50.45m
- CA$51.10m
Annual income statement for Defence Therapeutics, fiscal year end - June 30th, CAD millions except per share, conversion factor applied.
2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | 2025 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 2.86 | 7.32 | 6.55 | 12.8 | 3.19 |
| Operating Profit | -2.86 | -7.32 | -6.55 | -12.8 | -3.19 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -2.86 | -7.34 | -6.87 | -13.2 | -3.52 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -2.86 | -7.34 | -6.76 | -13.2 | -3.52 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -2.86 | -7.34 | -6.76 | -13.2 | -3.52 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -2.86 | -7.34 | -6.76 | -13.2 | -3.52 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.108 | -0.204 | -0.171 | -0.296 | -0.072 |